CL2015002641A1 - Método para el tratamiento de la enfermedad de parkinson. - Google Patents
Método para el tratamiento de la enfermedad de parkinson.Info
- Publication number
- CL2015002641A1 CL2015002641A1 CL2015002641A CL2015002641A CL2015002641A1 CL 2015002641 A1 CL2015002641 A1 CL 2015002641A1 CL 2015002641 A CL2015002641 A CL 2015002641A CL 2015002641 A CL2015002641 A CL 2015002641A CL 2015002641 A1 CL2015002641 A1 CL 2015002641A1
- Authority
- CL
- Chile
- Prior art keywords
- parkinson
- disease
- treatment
- tolcapona
- entacapona
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/121—Ketones acyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
LA PRESENTE INVENCIÓN PROPORCIONA UN MÉTODO PARA EL TRATAMIENTO DE UN TRASTORNO NEUROLOGICO O DEL MOVIMIENTO, POR EJEMPLO, LA ENFERMEDAD DE PARKINSON, EN UN INDIVIDUO EN NECESIDAD DEL MISMO, MEDIANTE ADMINISTRACIÓN PARENTERAL DE UNA COMPOSICIÓN QUE COMPRENDE CARBIDOPA Y LEVOPODA, O SALES FARMACEUTICAMENTE ACEPTABLES DE LOS MISMOS, Y LA ADMINISTRACIÓN ORAL CONCOMITANTE DE UN INHIBIDOR DE CATECOL-O-METIL TRANSFERASA (COMT), POR EJEMPLO, ENTACAPONA O TOLCAPONA.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361779357P | 2013-03-13 | 2013-03-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2015002641A1 true CL2015002641A1 (es) | 2016-03-18 |
Family
ID=50513395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2015002641A CL2015002641A1 (es) | 2013-03-13 | 2015-09-11 | Método para el tratamiento de la enfermedad de parkinson. |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20160022573A1 (es) |
| EP (2) | EP2968218B1 (es) |
| JP (2) | JP6472391B2 (es) |
| KR (1) | KR102209353B1 (es) |
| CN (2) | CN110935026A (es) |
| AU (1) | AU2014229127B2 (es) |
| BR (1) | BR112015022390A8 (es) |
| CA (1) | CA2904838C (es) |
| CL (1) | CL2015002641A1 (es) |
| DK (1) | DK2968218T3 (es) |
| ES (1) | ES2889626T3 (es) |
| HR (1) | HRP20211442T1 (es) |
| HU (1) | HUE056006T2 (es) |
| IL (1) | IL266648B (es) |
| MX (1) | MX365206B (es) |
| PL (1) | PL2968218T3 (es) |
| PT (1) | PT2968218T (es) |
| RU (2) | RU2018144700A (es) |
| SG (2) | SG11201507538UA (es) |
| WO (1) | WO2014141261A1 (es) |
| ZA (1) | ZA201507621B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201709016RA (en) | 2009-05-19 | 2017-11-29 | Neuroderm Ltd | Compositions for continuous administration of dopa decarboxylase inhibitors |
| HUE037897T2 (hu) | 2010-11-15 | 2018-09-28 | Neuroderm Ltd | Készítmények hatóanyagok transzdermális bevitelére |
| RS57047B1 (sr) | 2010-11-15 | 2018-05-31 | Neuroderm Ltd | Neprekidno davanje l dope, inhibitora dopa dekarboksilaze, inhibitora katehol-o-metil transferaze i kompozicije za iste |
| US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
| RS65060B1 (sr) * | 2014-03-13 | 2024-02-29 | Neuroderm Ltd | Sastavi inhibitora dopa dekarboksilaze |
| CA2959307C (en) | 2014-09-04 | 2023-03-28 | Lobsor Pharmaceuticals Aktiebolag | Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof |
| SI3209302T1 (sl) | 2014-10-21 | 2019-06-28 | Abb Vie Inc. | Predzdravila karbidope in L-dope in njihova uporaba za zdravljenje parkinsonove bolezni |
| MA41377A (fr) | 2015-01-20 | 2017-11-28 | Abbvie Inc | Gel intestinal de lévodopa et de carbidona et procédés d'utilisation |
| WO2017039525A1 (en) * | 2015-09-04 | 2017-03-09 | Lobsor Pharmaceuticals Aktiebolag | Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor |
| WO2017070293A1 (en) * | 2015-10-20 | 2017-04-27 | Ironwood Pharmaceuticals, Inc. | Phosphodiesterase 9 inhibitor and levodopa therapy |
| EP3275433A1 (en) * | 2016-07-29 | 2018-01-31 | Som Innovation Biotech S.L. | Sustained release composition comprising micronized tolcapone |
| RS61749B1 (sr) * | 2017-06-05 | 2021-05-31 | Dizlin Pharmaceuticals Ab | Rastvor levodope za infuziju |
| WO2019097120A1 (en) * | 2017-11-16 | 2019-05-23 | Orion Corporation | New use and pharmaceutical dosage forms |
| WO2019147934A1 (en) * | 2018-01-29 | 2019-08-01 | Sackner Bernstein Jonathan | Methods for dopamine modulation in human neurologic diseases |
| WO2019191353A1 (en) * | 2018-03-29 | 2019-10-03 | Riverside Pharmaceuticals Corporation | Levodopa fractionated dose composition and use |
| CN111701024B (zh) * | 2020-05-26 | 2022-05-24 | 上海京新生物医药有限公司 | 一种左旋多巴制剂及其制备方法及其应用 |
| US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
| US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
| US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
| WO2023282900A1 (en) * | 2021-07-08 | 2023-01-12 | Morehouse School Of Medicine | Method and system of diagnosing and treating neurodegenerative disease and seizures |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US4832957A (en) * | 1987-12-11 | 1989-05-23 | Merck & Co., Inc. | Controlled release combination of carbidopa/levodopa |
| FI109453B (fi) * | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Farmaseuttinen koostumus |
| MX2007015377A (es) * | 2005-06-08 | 2008-02-14 | Orion Corp | Forma de dosificacion oral. |
| TR200806646A2 (tr) * | 2008-09-03 | 2009-06-22 | Dr. F. Fri̇k İlaç San. Ve Ti̇c. A.Ş. | Entakapon, levodopa ve karbidoba içeren farmasötik kombinasyonlar |
| SG10201709016RA (en) * | 2009-05-19 | 2017-11-29 | Neuroderm Ltd | Compositions for continuous administration of dopa decarboxylase inhibitors |
| RS57047B1 (sr) * | 2010-11-15 | 2018-05-31 | Neuroderm Ltd | Neprekidno davanje l dope, inhibitora dopa dekarboksilaze, inhibitora katehol-o-metil transferaze i kompozicije za iste |
-
2014
- 2014-03-13 BR BR112015022390A patent/BR112015022390A8/pt not_active Application Discontinuation
- 2014-03-13 PL PL14718177T patent/PL2968218T3/pl unknown
- 2014-03-13 SG SG11201507538UA patent/SG11201507538UA/en unknown
- 2014-03-13 DK DK14718177.0T patent/DK2968218T3/da active
- 2014-03-13 KR KR1020157028984A patent/KR102209353B1/ko active IP Right Grant
- 2014-03-13 HU HUE14718177A patent/HUE056006T2/hu unknown
- 2014-03-13 ES ES14718177T patent/ES2889626T3/es active Active
- 2014-03-13 JP JP2015562555A patent/JP6472391B2/ja active Active
- 2014-03-13 RU RU2018144700A patent/RU2018144700A/ru not_active Application Discontinuation
- 2014-03-13 AU AU2014229127A patent/AU2014229127B2/en active Active
- 2014-03-13 WO PCT/IL2014/050261 patent/WO2014141261A1/en active Application Filing
- 2014-03-13 EP EP14718177.0A patent/EP2968218B1/en active Active
- 2014-03-13 PT PT147181770T patent/PT2968218T/pt unknown
- 2014-03-13 US US14/774,938 patent/US20160022573A1/en not_active Abandoned
- 2014-03-13 SG SG10201911731YA patent/SG10201911731YA/en unknown
- 2014-03-13 CA CA2904838A patent/CA2904838C/en active Active
- 2014-03-13 HR HRP20211442TT patent/HRP20211442T1/hr unknown
- 2014-03-13 RU RU2015143112A patent/RU2677278C2/ru active
- 2014-03-13 MX MX2015012561A patent/MX365206B/es active IP Right Grant
- 2014-03-13 EP EP21176202.6A patent/EP3892266A1/en not_active Withdrawn
- 2014-03-13 CN CN201911315631.1A patent/CN110935026A/zh active Pending
- 2014-03-13 CN CN201480027268.2A patent/CN105209029A/zh active Pending
-
2015
- 2015-09-11 CL CL2015002641A patent/CL2015002641A1/es unknown
- 2015-10-13 ZA ZA2015/07621A patent/ZA201507621B/en unknown
-
2019
- 2019-01-22 JP JP2019008215A patent/JP6625773B2/ja active Active
- 2019-05-15 IL IL266648A patent/IL266648B/en active IP Right Grant
-
2020
- 2020-05-18 US US16/876,911 patent/US20210093560A1/en not_active Abandoned
-
2022
- 2022-03-18 US US17/698,189 patent/US20230047847A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2015002641A1 (es) | Método para el tratamiento de la enfermedad de parkinson. | |
| CY1121826T1 (el) | Προφαρμακα καρβιντοπας και l-ντοπας και η χρηση τους στην αγωγη της νοσου parkinson | |
| CR20150242A (es) | Terapia adyuvante con inhibidores de quinasa de la familia tec | |
| CL2019001685A1 (es) | Composiciones de aminoácidos y métodos para el tratamiento de enfermedades y trastornos musculares. | |
| CL2018003754A1 (es) | Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo. | |
| CL2017000156A1 (es) | Procedimientos para el tratamiento de paramixovirus. | |
| BR112017008659A2 (pt) | ?métodos e compostos de agonista de gip? | |
| ECSP20011578A (es) | Composiciones de aminoácidos para el tratamiento de enfermedad hepática | |
| ECSP17013903A (es) | Protein kinase c inhibitors and methods of their use | |
| CR20150589A (es) | Compuestos de biheteroarilo y usos de los mismos | |
| DOP2016000291A (es) | Composiciones y métodos para modular la expresión del factor b del complemento | |
| CL2018000811A1 (es) | Formulaciones de aminoácidos de liberación modificada administradas por vía oral. | |
| BR112019003577A2 (pt) | métodos de tratamento da semente e produtos resultantes | |
| CO2018013020A2 (es) | Combinaciones farmacéuticas para el tratamiento del cáncer | |
| AR104755A1 (es) | Método para el tratamiento de enfermedad neurológica | |
| SV2017005354A (es) | Derivados de quinolizinona como inhibidores de pi3k | |
| ECSP13012603A (es) | Nueva formulacion del cetp(1) | |
| AR100028A1 (es) | Composiciones nutricionales que contienen ácido estearidónico | |
| AR106313A1 (es) | Combinación de levodopa deuterada con carbidopa y opicapona para el tratamiento de enfermedad de parkinson | |
| PE20200749A1 (es) | Moduladores de la expresion de enac | |
| BR112017001963A2 (pt) | composição farmacêutica oral, seu processo de preparação e método de tratamento | |
| BR112016012505A2 (pt) | composto para tratamento de hipoglicemia severa | |
| DOP2017000206A (es) | Agente terapéutico para disfunción del lóbulo frontal | |
| CL2016003271A1 (es) | Métodos para tratar infecciones | |
| AR106415A1 (es) | Composición farmacéutica para el tratamiento del dolor |